CRDL
Cardiol Therapeutics Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.20
+1.85%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.07
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.04
- EPS estimate
- -$0.09
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +19.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $9.50
- PT range
- $9.00 – $10
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026